Ye X, Zhu M, Che X, Wang H, Liang X, Wu C, et al. Lipopolysaccharide induces neuroinflammation in microglia by activating the MTOR pathway and downregulating Vps34 to inhibit autophagosome formation. J Neuroinflammation. 2020;17:18 pubmed publisher

Matthew Onabanjo A, Janusis J, Mercado Matos J, Carlisle A, Kim D, Levine F, et al. Beclin 1 promotes endosome recruitment of hepatocyte growth factor tyrosine kinase substrate (HRS) to suppress tumor proliferation. Cancer Res. 2019;: pubmed publisher

Holczer M, Hajdú B, Lôrincz T, Szarka A, Banhegyi G, Kapuy O. A Double Negative Feedback Loop between mTORC1 and AMPK Kinases Guarantees Precise Autophagy Induction upon Cellular Stress. Int J Mol Sci. 2019;20: pubmed publisher

Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, et al. In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned. Int J Mol Sci. 2019;20: pubmed publisher

Li Y, Song A, Fu Y, Walayat A, Yang M, Jian J, et al. Perinatal nicotine exposure alters Akt/GSK-3β/mTOR/autophagy signaling, leading to development of hypoxic-ischemic-sensitive phenotype in rat neonatal brain. Am J Physiol Regul Integr Comp Physiol. 2019;317:R803-R813 pubmed publisher

Suarez C, Lentini G, Ramaswamy R, Maynadier M, Aquilini E, Berry Sterkers L, et al. A lipid-binding protein mediates rhoptry discharge and invasion in Plasmodium falciparum and Toxoplasma gondii parasites. Nat Commun. 2019;10:4041 pubmed publisher

Xu F, Byström A, Johansson M. SSD1 suppresses phenotypes induced by the lack of Elongator-dependent tRNA modifications. PLoS Genet. 2019;15:e1008117 pubmed publisher

Wu J, Ardah M, Haikal C, Svanbergsson A, Diepenbroek M, Vaikath N, et al. Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. Transl Neurodegener. 2019;8:18 pubmed publisher

Perez Vidakovics M, Ure A, Arrías P, Romanowski V, Gomez R. Junín virus induces autophagy in human A549 cells. PLoS ONE. 2019;14:e0218730 pubmed publisher

Gambacurta A, Merlini G, Ruggiero C, Diedenhofen G, Battista N, Bari M, et al. Human osteogenic differentiation in Space: proteomic and epigenetic clues to better understand osteoporosis. Sci Rep. 2019;9:8343 pubmed publisher

Zhang D, Zhang T, Wang M, Wang X, Qin Y, Wu J, et al. TIGAR alleviates ischemia/reperfusion-induced autophagy and ischemic brain injury. Free Radic Biol Med. 2019;137:13-23 pubmed publisher

Wang X, Wu W, Gao J, Li Z, Dong B, Lin X, et al. Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res. 2019;38:140 pubmed publisher

Feleciano D, Juenemann K, Iburg M, Brás I, Holmberg C, Kirstein J. Crosstalk Between Chaperone-Mediated Protein Disaggregation and Proteolytic Pathways in Aging and Disease. Front Aging Neurosci. 2019;11:9 pubmed publisher

Neurohr G, Terry R, Lengefeld J, Bonney M, Brittingham G, Moretto F, et al. Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence. Cell. 2019;: pubmed publisher

Caution K, Pan A, Krause K, Badr A, Hamilton K, Vaidya A, et al. Methylomic correlates of autophagy activity in cystic fibrosis. J Cyst Fibros. 2019;18:491-500 pubmed publisher

Cheng A, Lu Y, Huang Q, Zuo Z. Attenuating oxygen-glucose deprivation-caused autophagosome accumulation may be involved in sevoflurane postconditioning-induced protection in human neuron-like cells. Eur J Pharmacol. 2019;849:84-95 pubmed publisher

Ma X, Zhang L, Song J, Nguyen E, Lee R, Rodgers S, et al. Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation. Nat Commun. 2019;10:296 pubmed publisher

Wu N, Yang D, Wu Z, Yan M, Zhang P, Liu Y. Insulin in high concentration recede cigarette smoke extract induced cellular senescence of airway epithelial cell through autophagy pathway. Biochem Biophys Res Commun. 2019;509:498-505 pubmed publisher

Sharif T, Martell E, Dai C, Ghassemi Rad M, Hanes M, Murphy P, et al. HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells. Autophagy. 2018;: pubmed publisher

Pal R, Palmieri M, Chaudhury A, Klisch T, di Ronza A, Neilson J, et al. Src regulates amino acid-mediated mTORC1 activation by disrupting GATOR1-Rag GTPase interaction. Nat Commun. 2018;9:4351 pubmed publisher

Cristofani R, Montagnani Marelli M, Cicardi M, Fontana F, Marzagalli M, Limonta P, et al. Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells. Cell Death Dis. 2018;9:889 pubmed publisher

Yu X, Teng X, Wang F, Zheng Y, Qu G, Zhou Y, et al. Metabolic control of regulatory T cell stability and function by TRAF3IP3 at the lysosome. J Exp Med. 2018;215:2463-2476 pubmed publisher

Lee J, Adler L, Karathia H, Carmel N, Rabinovich S, Auslander N, et al. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. Cell. 2018;174:1559-1570.e22 pubmed publisher

Hartley G, Chow L, Ammons D, Wheat W, Dow S. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation. Cancer Immunol Res. 2018;6:1260-1273 pubmed publisher

Surve M, Bhutda S, Datey A, Anil A, Rawat S, Pushpakaran A, et al. Heterogeneity in pneumolysin expression governs the fate of Streptococcus pneumoniae during blood-brain barrier trafficking. PLoS Pathog. 2018;14:e1007168 pubmed publisher

Thangaraj A, Periyasamy P, Liao K, Bendi V, Callen S, Pendyala G, et al. HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy. Autophagy. 2018;14:1596-1619 pubmed publisher

Sfakianos A, Mellor L, Pang Y, Kritsiligkou P, Needs H, Abou Hamdan H, et al. The mTOR-S6 kinase pathway promotes stress granule assembly. Cell Death Differ. 2018;25:1766-1780 pubmed publisher

Carbone C, Kern N, Fernandes R, Hui E, Su X, Garcia K, et al. In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase. Proc Natl Acad Sci U S A. 2017;114:E9338-E9345 pubmed publisher

Button R, Roberts S, Willis T, Hanemann C, Luo S. Accumulation of autophagosomes confers cytotoxicity. J Biol Chem. 2017;292:13599-13614 pubmed publisher

Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, et al. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics. PLoS ONE. 2015;10:e0141253 pubmed publisher

Franco A, Más Serrano P, Perez Contreras J, Jiménez L, Rodriguez D, Olivares J. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation. Transplant Proc. 2015;47:2364-7 pubmed publisher

Abbas K, Mubarak M, Zafar M, Aziz T, Abbas H, Muzaffar R, et al. Plasma cell-rich acute rejections in living-related kidney transplantation: a clinicopathological study of 50 cases. Clin Transplant. 2015;29:835-41 pubmed publisher

Spira D, Grözinger G, Domschke N, Bantleon R, Schmehl J, Wiskirchen J, et al. Cell Cycle Regulation of Smooth Muscle Cells--Searching for Inhibitors of Neointima Formation: Is Combretastatin A4 an Alternative to Sirolimus and Paclitaxel?. J Vasc Interv Radiol. 2015;26:1388-95 pubmed publisher

Li Y, Shen C, Zhu B, Shi F, Eisen H, Chen J. Persistent Antigen and Prolonged AKT-mTORC1 Activation Underlie Memory CD8 T Cell Impairment in the Absence of CD4 T Cells. J Immunol. 2015;195:1591-8 pubmed publisher

Reineke D, Müller Schweinitzer E, Winkler B, Kunz D, Konerding M, Grussenmeyer T, et al. Rapamycin impairs endothelial cell function in human internal thoracic arteries. Eur J Med Res. 2015;20:59 pubmed publisher

Traitanon O, Mathew J, La Monica G, Xu L, Mas V, Gallon L. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells. PLoS ONE. 2015;10:e0129658 pubmed publisher

Kloster Jensen K, Vethe N, Bremer S, Abadpour S, Korsgren O, Foss A, et al. Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro. Transpl Int. 2015;28:1152-61 pubmed publisher

Cho Y, Ha E, Baek I, Kim M, Cho C, Hwang S. Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® e. Molecules. 2015;20:9496-509 pubmed publisher

Solymosi T, Angi R, Basa Dénes O, Ránky S, Ötvös Z, Glavinas H, et al. Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method. Eur J Pharm Biopharm. 2015;94:135-40 pubmed publisher

Holczer M, Márton M, Kurucz A, Bánhegyi G, Kapuy O. A Comprehensive Systems Biological Study of Autophagy-Apoptosis Crosstalk during Endoplasmic Reticulum Stress. Biomed Res Int. 2015;2015:319589 pubmed publisher

Wang H, Zhang L, Yang X, Jin Y, Pei S, Zhang D, et al. PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer. Oncotarget. 2015;6:14385-98 pubmed

Revel Vilk S, Fischer U, Keller B, Nabhani S, Gámez Díaz L, Rensing Ehl A, et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation. Clin Immunol. 2015;159:84-92 pubmed publisher

Vrzal R, Zenata O, Bachleda P, Dvorak Z. The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes. Toxicol In Vitro. 2015;29:1088-99 pubmed publisher

Du J, Liu S, He J, Liu X, Qu Y, Yan W, et al. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget. 2015;6:14993-5007 pubmed

Kittipongdaja W, Wu X, Garner J, Liu X, Komas S, Hwang S, et al. Rapamycin Suppresses Tumor Growth and Alters the Metabolic Phenotype in T-Cell Lymphoma. J Invest Dermatol. 2015;135:2301-2308 pubmed publisher

Nalbandian A, Llewellyn K, Nguyen C, Yazdi P, Kimonis V. Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy. PLoS ONE. 2015;10:e0122888 pubmed publisher

Fan X, Wang J, Hou J, Lin C, Bensoussan A, Chang D, et al. Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. J Transl Med. 2015;13:92 pubmed publisher

Rosso Fernández C, Garnacho Montero J, Antonelli M, Dimopoulos G, Cisneros J. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protoc. Trials. 2015;16:102 pubmed publisher

Aizawa K, Takahari Y, Higashijima N, Serizawa K, Yogo K, Ishizuka N, et al. Nicorandil prevents sirolimus-induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation. J Pharmacol Sci. 2015;127:284-91 pubmed publisher

Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan E. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372:1213-22 pubmed publisher

Heylen L, Maertens J, Naesens M, Van Wijngaerden E, Lagrou K, Bammens B, et al. Invasive aspergillosis after kidney transplant: case-control study. Clin Infect Dis. 2015;60:1505-11 pubmed publisher

Scudellari M. Ageing research: Blood to blood. Nature. 2015;517:426-9 pubmed publisher

Otsuka F, Yahagi K, Ladich E, Kutys R, ALEXANDER R, Fowler D, et al. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. Circulation. 2015;131:322-4 pubmed publisher

Petrou P, Cunningham D, Shimel K, Harrington M, Hammel K, Cukras C, et al. Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci. 2014;56:330-8 pubmed publisher

Ferraris V. What the Human Genome Project hasn't told us: the epigenetics of development of esophageal squamous cell cancer. J Thorac Cardiovasc Surg. 2015;149:386-7 pubmed publisher

He C, Tsuchiyama S, Nguyen Q, Plyusnina E, Terrill S, Sahibzada S, et al. Enhanced longevity by ibuprofen, conserved in multiple species, occurs in yeast through inhibition of tryptophan import. PLoS Genet. 2014;10:e1004860 pubmed publisher

Olesen K, Tilsted H, Jensen L, Kaltoft A, Krusell L, Ravkilde J, et al. Long-term outcome of sirolimus-eluting and zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a Danish organization for randomized trials on clinical outcome III substudy). Am J Cardiol. 2015;115:298-302 pubmed publisher

Shah M, Shankar A, Gee I, Nash K, Hoare M, Gibbs P, et al. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients. Aliment Pharmacol Ther. 2015;41:379-92 pubmed publisher

McCormack F. Chronic sirolimus therapy for lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2014;190:1332-3 pubmed publisher

Poirier N, Dilek N, Mary C, Ville S, Coulon F, Branchereau J, et al. FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant. 2015;15:88-100 pubmed publisher

Kim J, Hong S, Lee J, Han S, Roh K, Lee K, et al. Insights into autophagosome maturation revealed by the structures of ATG5 with its interacting partners. Autophagy. 2015;11:75-87 pubmed publisher

Dominissini D. Genomics and Proteomics. Roadmap to the epitranscriptome. Science. 2014;346:1192 pubmed publisher

Gonzalo N, Dangas G, Ibanez B. Long-term favorable coronary healing after bioresorbable scaffold implantation: insights from OCT. J Am Coll Cardiol. 2014;64:2357-9 pubmed publisher

Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen N, Freire R, Dijkstra J, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014;64:2343-56 pubmed publisher

Franz D, Belousova E, Sparagana S, Bebin E, Frost M, Kuperman R, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014;15:1513-20 pubmed publisher

Northrup H. The mTOR inhibitor revolution rolls on. Lancet Oncol. 2014;15:1418-9 pubmed publisher

Marqués L, Núñez Córdoba J, Aguado L, Pretel M, Boixeda P, Nagore E, et al. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial. J Am Acad Dermatol. 2015;72:151-8.e1 pubmed publisher

Yagasaki R, Nakahara T, Mori A, Sakamoto K, Ishii K. Effects of mTOR inhibition on normal retinal vascular development in the mouse. Exp Eye Res. 2014;129:127-34 pubmed publisher

Zhang X, Wang X, Qin L, Xu T, Zhu Z, Zhong S, et al. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology. 2015;85:273.e1-7 pubmed publisher

Hsu H, Lin M, Jang Y, Kuo T, Liu C, Cheng T. The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells. J Thorac Cardiovasc Surg. 2015;149:378-85 pubmed publisher

Suarez O, Pardo M, Gonzalez S, Escobar Serna D, Castañeda D, Rodriguez D, et al. Diabetes mellitus and renal transplantation in adults: is there enough evidence for diagnosis, treatment, and prevention of new-onset diabetes after renal transplantation?. Transplant Proc. 2014;46:3015-20 pubmed publisher

Caiazzo R, Vantyghem M, Raverdi V, Bonner C, Gmyr V, Defrance F, et al. Impact of Procedure-Related Complications on Long-term Islet Transplantation Outcome. Transplantation. 2015;99:979-84 pubmed publisher

Piatek C, Raja G, Ji L, Gitlitz B, Dorff T, Quinn D, et al. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014;74:1227-34 pubmed publisher

Zheng X, Xie Z, Zhu Z, Liu Z, Wang Y, Wei L, et al. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. PLoS ONE. 2014;9:e111536 pubmed publisher

Check Hayden E. Pet dogs set to test anti-ageing drug. Nature. 2014;514:546 pubmed publisher

Su J, Kelly R, Grogan T, Elashoff D, Alejos J. Extracorporeal membrane oxygenation support after pediatric orthotopic heart transplantation. Pediatr Transplant. 2015;19:68-75 pubmed publisher

Zhu J, Lu T, Yue S, Shen X, Gao F, Busuttil R, et al. Rapamycin protection of livers from ischemia and reperfusion injury is dependent on both autophagy induction and mammalian target of rapamycin complex 2-Akt activation. Transplantation. 2015;99:48-55 pubmed publisher

Zemp F, McKenzie B, Lun X, Reilly K, McFadden G, Yong V, et al. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. Cancer Res. 2014;74:7260-73 pubmed publisher

Yao J, Taveira DaSilva A, Jones A, Julien Williams P, Stylianou M, Moss J. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2014;190:1273-82 pubmed publisher

Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014;10:1013-9 pubmed publisher

Van Laecke S, Nagler E, Vanholder R. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:1553 pubmed publisher

Canaud G, Terzi F. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:1554-5 pubmed publisher

Grabiner B, Van Allen E, Amin Mansour A, Taylor Weiner A, Rosenberg M, Gray N, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371:1426-33 pubmed publisher

Park K, Kim H, Lee J, Lee K, Jeong I, Song C, et al. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. Anticancer Res. 2014;34:5723-8 pubmed

Lin H, Chang K, Hung C, Kuo C, Hwang S, Chen H, et al. Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines. BMC Immunol. 2014;15:37 pubmed publisher

Serruys P, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes . Lancet. 2015;385:43-54 pubmed publisher

Di Mario C, Caiazzo G. Biodegradable stents: the golden future of angioplasty?. Lancet. 2015;385:10-12 pubmed publisher

Chuang Y, Ruan S, Huang C. Compelling results of adjuvant therapy with sirolimus for severe H1N1 pneumonia. Crit Care Med. 2014;42:e687-8 pubmed publisher

Stojkovic S, Neskovic A, Mehmedbegovic Z, Kafedzic S, Ostojic M, Nedeljkovic M, et al. Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. Fundam Clin Pharmacol. 2015;29:95-105 pubmed publisher

Ding L, Heremans Y, Pipeleers D, Ling Z, Heimberg H, Gysemans C, et al. Clinical Immunosuppressants Inhibit Inflammatory, Proliferative, and Reprogramming Potential, But Not Angiogenesis of Human Pancreatic Duct Cells. Cell Transplant. 2015;24:1585-98 pubmed publisher

Mehilli J, Massberg S. Revisiting the BIOSCIENCE of drug-eluting stent technology. Lancet. 2014;384:2086-8 pubmed publisher

Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384:2111-22 pubmed publisher

Taveira DaSilva A, Jones A, Julien Williams P, Stylianou M, Moss J. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis. Chest. 2015;147:180-187 pubmed publisher

Van Boven N, Windecker S, Umans V, van Domburg R, Kardys I, Akkerhuis K, et al. Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF. Heart. 2015;101:50-7 pubmed publisher

Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, et al. Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit. 2015;37:395-9 pubmed publisher

Wang C, Cigliano A, Jiang L, Li X, Fan B, Pilo M, et al. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Hepatology. 2015;61:200-13 pubmed publisher

Guerra E, Byrne R, Kastrati A. Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opin Pharmacother. 2014;15:2155-71 pubmed publisher

Nonnenmacher L, Westhoff M, Fulda S, Karpel Massler G, Halatsch M, Engelke J, et al. RIST: a potent new combination therapy for glioblastoma. Int J Cancer. 2015;136:E173-87 pubmed publisher

Grossman J, Cuellar Rodríguez J, Gea Banacloche J, Zerbe C, Calvo K, Hughes T, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Biol Blood Marrow Transplant. 2014;20:1940-8 pubmed publisher

Saba N, Hurwitz S, Magliocca K, Kim S, Owonikoko T, Harvey D, et al. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2014;120:3940-51 pubmed publisher

Hoerning A, Wilde B, Wang J, Tebbe B, Jing L, Wang X, et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. Transplantation. 2015;99:210-9 pubmed publisher

Stevens R, Foster K, Miles C, Lane J, Kalil A, Florescu D, et al. A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation. 2015;99:197-209 pubmed publisher

Giordano S, Dodson M, Ravi S, Redmann M, Ouyang X, Darley Usmar V, et al. Bioenergetic adaptation in response to autophagy regulators during rotenone exposure. J Neurochem. 2014;131:625-33 pubmed publisher

Ferolla P. Medical treatment of advanced thoracic neuroendocrine tumors. Thorac Surg Clin. 2014;24:351-5 pubmed publisher

Zhu A, Kudo M, Assenat E, Cattan S, Kang Y, Lim H, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312:57-67 pubmed publisher

Hsieh M, Fitzhugh C, Weitzel R, Link M, Coles W, Zhao X, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312:48-56 pubmed publisher

King A, DiPersio J. Reconsideration of age as a contraindication for curative therapy of sickle cell disease. JAMA. 2014;312:33-4 pubmed publisher

Eikelboom J, Weitz J. The mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:369-71 pubmed publisher

Canaud G, Bienaime F, Tabarin F, Bataillon G, Seilhean D, Noel L, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:303-12 pubmed publisher

Ganesan S, Moussavi Nik S, Newman M, Lardelli M. Identification and expression analysis of the zebrafish orthologues of the mammalian MAP1LC3 gene family. Exp Cell Res. 2014;328:228-37 pubmed publisher

Rostaing L, Christiaans M, Kovarik J, Pascual J. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. Ann Transplant. 2014;19:337-45 pubmed publisher

Jang S, Kang M. Improved oral absorption and chemical stability of everolimus via preparation of solid dispersion using solvent wetting technique. Int J Pharm. 2014;473:187-93 pubmed publisher

Fekete T, Pazmandi K, Szabo A, Bacsi A, Koncz G, Rajnavolgyi E. The antiviral immune response in human conventional dendritic cells is controlled by the mammalian target of rapamycin. J Leukoc Biol. 2014;96:579-89 pubmed publisher

Wang W, Yu L. Acute respiratory distress attributed to sirolimus in solid organ transplant recipients. Am J Emerg Med. 2015;33:124.e1-4 pubmed publisher

Huynh T, Santini E, Klann E. Requirement of Mammalian target of rapamycin complex 1 downstream effectors in cued fear memory reconsolidation and its persistence. J Neurosci. 2014;34:9034-9 pubmed publisher

Urbanellis P, Shyu W, Khattar R, Wang J, Zakharova A, He W, et al. The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts. Immunology. 2015;144:91-106 pubmed publisher

Andre F, Gianni L. BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authors' reply. Lancet Oncol. 2014;15:e304-5 pubmed publisher

Glover T, Kew V, Reeves M. Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro. J Gen Virol. 2014;95:2260-2266 pubmed publisher

Oh C, Huh K, Ha J, Kim Y, Kim Y, Kim Y. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Transplantation. 2015;99:180-6 pubmed publisher

Benson C, Vitfell Rasmussen J, Maruzzo M, Fisher C, Tunariu N, Mitchell S, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014;34:3663-8 pubmed

Chao T, Chang G, Chen W, Chen P, Mao F. The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells. Anticancer Res. 2014;34:3329-35 pubmed

Ceppi F, Duval M, Teira P, Therrien R, Ovetchkine P, Mallette B, et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymp. J Pediatr Hematol Oncol. 2014;36:e319-21 pubmed publisher

Kim K, Chung B, Kim B, Cho M, Yang C. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology. 2015;144:68-78 pubmed publisher

Schindler C, Partap U, Patchen B, Swoap S. Chronic rapamycin treatment causes diabetes in male mice. Am J Physiol Regul Integr Comp Physiol. 2014;307:R434-43 pubmed publisher

. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2014;106: pubmed publisher

Wang Z, Xu F, Yuan N, Niu Y, Lin W, Cao Y, et al. Rapamycin inhibits pre-B acute lymphoblastic leukemia cells by downregulating DNA and RNA polymerases. Leuk Res. 2014;38:940-7 pubmed publisher

Gao H, Ao M, Wang H, Yu L. Rapamycin represses myotube hypertrophy and preserves viability of C2C12 cells during myogenesis in vitro. Transplantation. 2014;98:139-47 pubmed publisher

Marits P, Wikstrom A, Popadic D, Winqvist O, Thunberg S. Evaluation of T and B lymphocyte function in clinical practice using a flow cytometry based proliferation assay. Clin Immunol. 2014;153:332-42 pubmed publisher

Powles T, Foreshew S, Shamash J, Sarwar N, Crabb S, Sahdev A, et al. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. Eur J Cancer. 2014;50:2057-64 pubmed publisher

Zhong W, Zhu H, Sheng F, Tian Y, Zhou J, Chen Y, et al. Activation of the MAPK11/12/13/14 (p38 MAPK) pathway regulates the transcription of autophagy genes in response to oxidative stress induced by a novel copper complex in HeLa cells. Autophagy. 2014;10:1285-300 pubmed publisher

Vicens R, Jensen C, Korivi B, Bhosale P. Malignant renal epithelioid angiomyolipoma with liver metastasis after resection: a case report with multimodality imaging and review of the literature. J Comput Assist Tomogr. 2014;38:574-7 pubmed publisher

Nakagawa M, Otake H, Shinke T, Takaya T, Kozuki A, Hariki H, et al. Analysis by optical coherence tomography of long-term arterial healing after implantation of different types of stents. Can J Cardiol. 2014;30:904-11 pubmed publisher

Lavi S, Camuglia A. Illuminating and alarming insights into vascular healing. Can J Cardiol. 2014;30:855-7 pubmed publisher

Zeng C, Fan Y, Wu J, Shi S, Chen Z, Zhong Y, et al. Podocyte autophagic activity plays a protective role in renal injury and delays the progression of podocytopathies. J Pathol. 2014;234:203-13 pubmed publisher

Von Visger J, Gunay Y, Andreoni K, Bhatt U, Nori U, Pesavento T, et al. The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression. Clin Transplant. 2014;28:845-54 pubmed publisher

. News products to avoid. Prescrire Int. 2014;23:105 pubmed

Weiss B, Widemann B, Wolters P, Dombi E, Vinks A, Cantor A, et al. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014;61:982-6 pubmed

Lim S, Doh K, Jin L, Heo S, Zheng Y, Bae S, et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation. 2014;98:22-8 pubmed publisher

McRee A, Davies J, Sanoff H, Goldberg R, Bernard S, Dees E, et al. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014;74:117-23 pubmed publisher

Park K, Kang S, Kang H, Koo B, Park B, Cha K, et al. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment o. J Am Coll Cardiol. 2014;63:2805-16 pubmed publisher

Wilson S, Chia S. When is downstream pathway inhibition important?. Lancet Oncol. 2014;15:541-2 pubmed publisher

Ramírez A, Pacheco C, Aguayo L, Opazo C. Rapamycin protects against Aβ-induced synaptotoxicity by increasing presynaptic activity in hippocampal neurons. Biochim Biophys Acta. 2014;1842:1495-501 pubmed publisher

Pfisterer S, Bakula D, Frickey T, Cezanne A, Brigger D, Tschan M, et al. Lipid droplet and early autophagosomal membrane targeting of Atg2A and Atg14L in human tumor cells. J Lipid Res. 2014;55:1267-78 pubmed publisher

Swer P, Lohia R, Saran S. Analysis of rapamycin induced autophagy in Dictyostelium discoideum. Indian J Exp Biol. 2014;52:295-304 pubmed

Fleuren E, Versleijen Jonkers Y, Roeffen M, Franssen G, Flucke U, Houghton P, et al. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. Int J Cancer. 2014;135:2770-82 pubmed publisher

Andre F, O Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580-91 pubmed publisher

Fruhwürth S, Krieger S, Winter K, Rosner M, Mikula M, Weichhart T, et al. Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production. Biochim Biophys Acta. 2014;1841:944-53 pubmed publisher

Tramsen L, Schmidt S, Roeger F, Schubert R, Salzmann Manrique E, Latge J, et al. Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells. Infect Immun. 2014;82:2649-56 pubmed publisher

Montezano A, Touyz R. Mammalian target of rapamycin: a novel pathway in vascular calcification. Can J Cardiol. 2014;30:482-4 pubmed publisher

Hu J, Schacher S. Persistent long-term facilitation at an identified synapse becomes labile with activation of short-term heterosynaptic plasticity. J Neurosci. 2014;34:4776-85 pubmed publisher

Piha Paul S, Shin S, Vats T, Guha Thakurta N, Aaron J, Rytting M, et al. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014;34:1939-45 pubmed

Palumbo S, Tini P, Toscano M, Allavena G, Angeletti F, Manai F, et al. Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells. J Cell Physiol. 2014;229:1863-73 pubmed publisher

Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment. Jpn J Clin Oncol. 2014;44:479-85 pubmed publisher

Wang C, Yan Y, Hu L, Zhao L, Yang P, Moorhead J, et al. Rapamycin-mediated CD36 translational suppression contributes to alleviation of hepatic steatosis. Biochem Biophys Res Commun. 2014;447:57-63 pubmed publisher

Hamdulay S, Wang B, Calay D, Kiprianos A, Cole J, Dumont O, et al. Synergistic therapeutic vascular cytoprotection against complement-mediated injury induced via a PKCα-, AMPK-, and CREB-dependent pathway. J Immunol. 2014;192:4316-27 pubmed publisher

Roh J, Kim Y, Ahn J, Yun S, Lee J, Ge J, et al. Readmission rate after coronary artery bypass grafting versus percutaneous coronary intervention for unprotected left main coronary artery narrowing. Am J Cardiol. 2014;113:1639-46 pubmed publisher

Lopes P, Fuhrmann A, Sereno J, Espinoza D, Pereira M, Eriksson J, et al. Short and long term in vivo effects of Cyclosporine A and Sirolimus on genes and proteins involved in lipid metabolism in Wistar rats. Metabolism. 2014;63:702-15 pubmed publisher

Paul D, Grevengoed T, Pascual F, Ellis J, Willis M, Coleman R. Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin. Biochim Biophys Acta. 2014;1841:880-7 pubmed publisher

Glorieux C, Auquier J, Dejeans N, Sid B, Demoulin J, Bertrand L, et al. Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway. Biochem Pharmacol. 2014;89:217-23 pubmed publisher

Rouer M, Xu B, Xuan H, Tanaka H, Fujimura N, Glover K, et al. Rapamycin limits the growth of established experimental abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2014;47:493-500 pubmed publisher

Festuccia W, Blanchard P, Belchior T, Chimin P, Paschoal V, Magdalon J, et al. PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats. Am J Physiol Endocrinol Metab. 2014;306:E1046-54 pubmed publisher

Kaneko M, Nozawa H, Hiyoshi M, Tada N, Murono K, Nirei T, et al. Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells. J Cancer Res Clin Oncol. 2014;140:769-81 pubmed publisher

Calvo E, Grünwald V, Bellmunt J. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. Eur J Cancer. 2014;50:1321-9 pubmed publisher

Maschan M, Bobrynina V, Khachatryan L, Kalinina I, Solopova G, Avdonin P, et al. Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N-RAS mutation. Pediatr Blood Cancer. 2014;61:1871-3 pubmed publisher

Wang M, Popplewell L, Collins R, Winter J, Goy A, Kaminski M, et al. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014;165:510-8 pubmed publisher

Liu G, Bi Y, Wang R, Yang H, Zhang Y, Wang X, et al. Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells. J Immunol. 2014;192:3068-79 pubmed publisher

Maute L, Grünwald V, Weikert S, Kube U, Gauler T, Kahl C, et al. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis. J Cancer Res Clin Oncol. 2014;140:823-7 pubmed publisher

Husseinzadeh N, Husseinzadeh H. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol. 2014;133:375-81 pubmed publisher

Benedetto U, Raja S, Soliman R, Albanese A, Jothidasan A, Ilsley C, et al. Minimally invasive direct coronary artery bypass improves late survival compared with drug-eluting stents in isolated proximal left anterior descending artery disease: a 10-year follow-up, single-center, propensity score analysis. J Thorac Cardiovasc Surg. 2014;148:1316-22 pubmed publisher

Mukai Y, Takeda Y, Nakahira S, Katsura Y, Kusama H, Hashimoto N, et al. [A case of massive pancreatic neuroendocrine carcinoma successfully treated with surgical resection and postoperative everolimus administration]. Gan To Kagaku Ryoho. 2013;40:1887-9 pubmed

Bhorade S. Invited commentary. Ann Thorac Surg. 2014;97:274-5 pubmed publisher

Vafai S, Mootha V. Medicine. A common pathway for a rare disease?. Science. 2013;342:1453-4 pubmed publisher

Groenewoud M, Zwartkruis F. Rheb and mammalian target of rapamycin in mitochondrial homoeostasis. Open Biol. 2013;3:130185 pubmed publisher

Melancon K, Mulgaonkar S, Delcoro C, Wiland A, McCague K, Shihab F. Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis. Transplantation. 2013;96:1073-81 pubmed publisher

Fowler D. Rapamycin-resistant effector T-cell therapy. Immunol Rev. 2014;257:210-25 pubmed publisher

Gandhi L, Bahleda R, Tolaney S, Kwak E, Cleary J, Pandya S, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014;32:68-75 pubmed publisher

Burger A, Vasilyev A, Tomar R, Selig M, Nielsen G, Peterson R, et al. A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12. Dis Model Mech. 2014;7:907-13 pubmed publisher

Morgan P, Brown N, Tredger J. A direct method for the measurement of everolimus and sirolimus in whole blood by LC-MS/MS using an isotopic everolimus internal standard. Ther Drug Monit. 2014;36:358-65 pubmed publisher

Boers Doets C, Raber Durlacher J, Treister N, Epstein J, Arends A, Wiersma D, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013;9:1883-92 pubmed publisher

Mulas M, Maxia A, Dessì S, Mandas A. Cholesterol esterification as a mediator of proliferation of vascular smooth muscle cells and peripheral blood mononuclear cells during atherogenesis. J Vasc Res. 2014;51:14-26 pubmed publisher

James S, Takken W, Collins F, Gottlieb M. Needs for monitoring mosquito transmission of malaria in a pre-elimination world. Am J Trop Med Hyg. 2014;90:6-10 pubmed publisher

Aguilera D, Flamini R, Mazewski C, Schniederjan M, Hayes L, Boydston W, et al. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus. J Pediatr Hematol Oncol. 2014;36:e448-51 pubmed publisher

Liu S, Tsang N, Chiang W, Chang K, Hsueh C, Liang Y, et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Invest. 2013;123:5269-83 pubmed publisher

Brener S, Kereiakes D, Simonton C, Rizvi A, Newman W, Mastali K, et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Ar. Am Heart J. 2013;166:1035-42 pubmed publisher

Leung A, Southern D, Galbraith P, Knudtson M, Philpott A, Ghali W. Time dependency of outcomes for drug-eluting vs bare-metal stents. Can J Cardiol. 2013;29:1616-22 pubmed publisher

Leslie M. Biomedicine. A putative antiaging drug takes a step from mice to men. Science. 2013;342:789 pubmed publisher

Johnson S, Yanos M, Kayser E, Quintana A, Sangesland M, Castanza A, et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013;342:1524-8 pubmed publisher

Paglino C, Procopio G, Sabbatini R, Bellmunt J, Schmidinger M, Bearz A, et al. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. Anticancer Res. 2013;33:4999-5004 pubmed

Lai L, Lilley B, Sanes J, McMahon A. Lkb1/Stk11 regulation of mTOR signaling controls the transition of chondrocyte fates and suppresses skeletal tumor formation. Proc Natl Acad Sci U S A. 2013;110:19450-5 pubmed publisher

Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan E, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625 pubmed publisher

Navarese E, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari D, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530 pubmed publisher

Chu L, Huang Y, Lee J, Huang L, Chen W, Lin Y, et al. Single-virus tracking approach to reveal the interaction of Dengue virus with autophagy during the early stage of infection. J Biomed Opt. 2014;19:011018 pubmed publisher

Molina A, Hutson T, Larkin J, Gold A, Wood K, Carter D, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2014;73:181-9 pubmed publisher

Byrne R, Kastrati A. Drug-eluting stent trials: too much non-inferiority, too little progress?. Lancet. 2014;383:386-8 pubmed publisher

von Birgelen C, Sen H, Lam M, Danse P, Jessurun G, Hautvast R, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383:413-23 pubmed publisher

Feres F, Costa R, Abizaid A, Leon M, Marin Neto J, Botelho R, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-22 pubmed publisher

Liistro F, Porto I, Angioli P, Grotti S, Ducci K, Falsini G, et al. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial. Am Heart J. 2013;166:920-6 pubmed publisher

Valgimigli M, Patialiakas A, Thury A, Colangelo S, Campo G, Tebaldi M, et al. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprin. Am Heart J. 2013;166:831-8 pubmed publisher

Lucas C, Kuehn H, Zhao F, Niemela J, Deenick E, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15:88-97 pubmed publisher

Sakamoto T, Weng J, Hara T, Yoshino S, Kozuka Hata H, Oyama M, et al. Hypoxia-inducible factor 1 regulation through cross talk between mTOR and MT1-MMP. Mol Cell Biol. 2014;34:30-42 pubmed publisher

Vicier C, Dieci M, Andre F. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. Curr Opin Oncol. 2013;25:587-93 pubmed publisher

Kang S, Pacold M, Cervantes C, Lim D, Lou H, Ottina K, et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science. 2013;341:1236566 pubmed publisher

Barlow A, Nicholson M, Herbert T. Evidence for rapamycin toxicity in pancreatic ?-cells and a review of the underlying molecular mechanisms. Diabetes. 2013;62:2674-82 pubmed publisher

Liu W, Lin J, Cheng Y, Zhang L, Huang J, Wu Z, et al. FIM-A, a phosphorus-containing sirolimus, inhibits the angiogenesis and proliferation of osteosarcomas. Oncol Res. 2013;20:319-26 pubmed

Albert B, Mathon J, Shukla A, Saad H, Normand C, Leger Silvestre I, et al. Systematic characterization of the conformation and dynamics of budding yeast chromosome XII. J Cell Biol. 2013;202:201-10 pubmed publisher

Cho D. Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma. Cancer J. 2013;19:311-5 pubmed publisher

Macunluoglu B, Atakan A, Gokce I, Ari E, Tulunay A, Demiralp E, et al. Effects of rapamycin and tacrolimus on mature endothelial cells and endothelial progenitor cells. J Pak Med Assoc. 2012;62:822-5 pubmed

Zhang J, Francois R, Iyer R, Seshadri M, Zajac Kaye M, Hochwald S. Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst. 2013;105:1005-17 pubmed publisher

Ciruelos E, Cortes Funes H, Ghanem I, Manso L, Arteaga C. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anticancer Drugs. 2013;24:769-80 pubmed publisher

Hadji P, Coleman R, Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol. 2013;87:101-11 pubmed publisher

Beigh M, Showkat M, Hussain M, Andrabi K. Loss of hydrophobic motif and activation loop phosphorylation is a consequence and not the mechanism of S6 kinase 1 inhibition by rapamycin. J Biol Regul Homeost Agents. 2013;27:399-408 pubmed

Brunner E, Lehle K, Hirt S, Schmid C, von Suesskind Schwendi M. Everolimus's influence on persistent acute rejection after experimental lung transplantation. Adv Clin Exp Med. 2013;22:355-9 pubmed

Xie J, Zhang X, Fang B, He G, Zhao Y, Wu D. Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;). Chin Med Sci J. 2013;28:127-8 pubmed

Pourdehnad M, Truitt M, Siddiqi I, Ducker G, Shokat K, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013;110:11988-93 pubmed publisher

Maj Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, et al. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy. Oncology. 2013;85:8-13 pubmed publisher

Soliman G. The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses. Nutrients. 2013;5:2231-57 pubmed publisher

Lim D, Park Y, Kim S, Jeong S, Kim S. Diagnostic value of tolerance-related gene expression measured in the recipient alloantigen-reactive T cell fraction. Clin Immunol. 2013;148:219-26 pubmed publisher

Sundin T, PEFFLEY D, Hentosh P. eIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase. Exp Cell Res. 2013;319:2103-2112 pubmed publisher

Fowles J, Denton C, Gustafson D. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Vet Comp Oncol. 2015;13:288-304 pubmed publisher

Campone M, Bachelot T, Gnant M, Deleu I, Rugo H, Pistilli B, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer. 2013;49:2621-32 pubmed publisher

Kotulska K, Borkowska J, Jozwiak S. Possible prevention of tuberous sclerosis complex lesions. Pediatrics. 2013;132:e239-42 pubmed publisher

Chinnaiyan P, Won M, Wen P, Rojiani A, Wendland M, DiPetrillo T, et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013;86:880-4 pubmed publisher

Shin Y, Hyon J, Choi W, Yi K, Chung E, Chung T, et al. Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-β1/ERK pathways regulation. Invest Ophthalmol Vis Sci. 2013;54:4452-8 pubmed publisher

Demetri G, Chawla S, Ray Coquard I, Le Cesne A, Staddon A, Milhem M, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31:2485-92 pubmed publisher

Li X, Zhang J, Chen Z, Yang L, Xing X, Ma X, et al. Both PI3K- and mTOR-signaling pathways take part in CVB3-induced apoptosis of Hela cells. DNA Cell Biol. 2013;32:359-70 pubmed publisher

Berdichevsky Y, Dryer A, Saponjian Y, Mahoney M, Pimentel C, Lucini C, et al. PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy. J Neurosci. 2013;33:9056-67 pubmed publisher

Houtkooper R, Mouchiroud L, Ryu D, Moullan N, Katsyuba E, Knott G, et al. Mitonuclear protein imbalance as a conserved longevity mechanism. Nature. 2013;497:451-7 pubmed publisher

. [An advance in the management of breast cancer]. Soins. 2013;:12 pubmed

Flechner S, Gurkan A, Hartmann A, Legendre C, Russ G, Campistol J, et al. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation. 2013;95:1233-41 pubmed publisher

Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62:181-190 pubmed publisher

Abhyankar A, Prajapati J, Reddy S. Early vascular healing with biodegradable polymer coated sirolimus-eluting coronary stent implantation: assessed by optical coherence tomography results at 4-month follow-up. Minerva Cardioangiol. 2013;61:313-22 pubmed

Tinker A, Ellard S, Welch S, Moens F, Allo G, Tsao M, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013;130:269-74 pubmed publisher

Aso E, Ferrer I. It may be possible to delay the onset of neurodegenerative diseases with an immunosuppressive drug (rapamycin). Expert Opin Biol Ther. 2013;13:1215-9 pubmed publisher

Wong M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J. 2013;36:40-50 pubmed publisher

Chong Z, Yao Q, Li H. The rationale of targeting mammalian target of rapamycin for ischemic stroke. Cell Signal. 2013;25:1598-607 pubmed publisher

Sharp Z, Curiel T, Livi C. Chronic mechanistic target of rapamycin inhibition: preventing cancer to delay aging, or vice versa?. Interdiscip Top Gerontol. 2013;38:1-16 pubmed publisher

Nikoueinejad H, Soleimani A, Mirshafiey A, Amirzargar A, Sarrafnejad A, Kamkar I, et al. Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant. Exp Clin Transplant. 2013;11:12-6 pubmed

Dwyer J, Duman R. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry. 2013;73:1189-98 pubmed publisher

Malaguti P, Vari S, Cognetti F, Fabi A. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Anticancer Res. 2013;33:21-8 pubmed

Upadhyay V, Trivedi V, Shah G, Yadav M, Shrivastav P. Rapid and sensitive UPLC-MS-MS determination of tacrolimus in Wistar rats and human blood. J Chromatogr Sci. 2014;52:59-67 pubmed publisher

Gurk Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation. 2012;94:659-68 pubmed publisher

Zardavas D, Fumagalli D, Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. Curr Opin Oncol. 2012;24:623-34 pubmed publisher

Pan Y, Nishida Y, Wang M, Verdin E. Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review. Gerontology. 2012;58:524-30 pubmed publisher

Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94:547-61 pubmed

Li S, Brown M, Goldstein J. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A. 2010;107:3441-6 pubmed publisher

Sasai N, Agata N, Inoue Miyazu M, Kawakami K, Kobayashi K, Sokabe M, et al. Involvement of PI3K/Akt/TOR pathway in stretch-induced hypertrophy of myotubes. Muscle Nerve. 2010;41:100-6 pubmed publisher

Schonbrun M, Laor D, López Maury L, Bahler J, Kupiec M, Weisman R. TOR complex 2 controls gene silencing, telomere length maintenance, and survival under DNA-damaging conditions. Mol Cell Biol. 2009;29:4584-94 pubmed publisher

Liu H, Wang P, Song W, Sun X. Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways. FASEB J. 2009;23:3383-92 pubmed publisher

Foster D, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009;8:1026-9 pubmed

Dorsey F, Steeves M, Prater S, Schröter T, Cleveland J. Monitoring the autophagy pathway in cancer. Methods Enzymol. 2009;453:251-71 pubmed publisher

Bieri M, Oroszlan M, Zuppinger C, Mohacsi P. Biosynthesis and expression of VE-cadherin is regulated by the PI3K/mTOR signaling pathway. Mol Immunol. 2009;46:866-72 pubmed publisher

Chiang G, Abraham R. Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007;13:433-42 pubmed

Corradetti M, Guan K. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene. 2006;25:6347-60 pubmed

Mita M, Mita A, Rowinsky E. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther. 2003;2:S169-77 pubmed

Sehgal S, Bansbach C. Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann N Y Acad Sci. 1993;685:58-67 pubmed